Summary of Conference Call on CKBA Clinical Phase II Data Company and Industry - **Company**: CKBA - **Industry**: Pharmaceutical, specifically focusing on dermatological treatments and neurodegenerative diseases Key Points and Arguments Clinical Trial Results - CKBA demonstrated a differentiated advantage in treating vitiligo by inhibiting tissue-resident memory T cell binding and reducing reactive oxygen species (ROS) in melanocytes, achieving both immune modulation and melanin production [1][7] - The Phase II clinical trial results indicated that facial vitiligo treatment was more effective than neck treatment, attributed to greater natural light exposure promoting melanocyte differentiation and secretion [1][12] - In the high-quality group, the improvement rate for facial skin color reached 50%, significantly higher than the 18% in the MG group [1][16] Future Clinical Plans - The company plans to initiate Phase III clinical trials by the end of the year, focusing on facial efficacy and expanding the sample size to include patients aged 12-65 [1][2] - A breakthrough therapy application will be submitted soon to support the Phase III trial [2] Safety and Efficacy - CKBA's adverse event rate is only 18%, significantly lower than the 60% rate associated with traditional treatments like Jak inhibitors, making it suitable for long-term maintenance therapy, especially for children aged 2-12 [1][7][19] - The drug is expected to be the first treatment specifically for vitiligo in children aged 2-12 globally, addressing a strong demand in China where there are approximately 12 million such patients [3][18] Pricing Strategy - The annual treatment cost for CKBA is estimated to be around 10,000 to 20,000 yuan, significantly lower than the 150,000 yuan for traditional treatments, enhancing drug accessibility [3][8] Other Research Initiatives - NKBA, a high bioavailability derivative of AKBA, has initiated preclinical studies for Alzheimer's disease and anti-aging, with IND submission expected in Q3 next year [1][5] - The company has submitted a Phase II clinical application for rosacea and plans to start clinical trials shortly, with a treatment cycle of about three months [1][6] Market Position and Competitive Advantage - CKBA's unique mechanism of action and safety profile position it favorably against existing treatments, making it particularly appealing for long-term use in pediatric patients [1][7][19] - The company aims to conduct head-to-head comparisons with existing treatments like Ruxolitinib once it is approved, to establish a clear safety and efficacy advantage [18] Clinical Management Challenges - The management of clinical trials for vitiligo is complex due to long cycles and the need for placebo controls, but the company is confident in improving data collection and trial management in Phase III [15] Conclusion - CKBA is poised to make significant advancements in the treatment of vitiligo, particularly in pediatric populations, with a strong focus on safety, efficacy, and affordability, while also exploring new therapeutic avenues in neurodegenerative diseases.

Investment Rating - The report maintains a "Positive" outlook for the industry, particularly highlighting the demand for new drugs for rosacea [9][25]. Core Insights - There is a significant demand for new drugs to treat rosacea, with an estimated prevalence of 3.48% in China, translating to approximately 49 million patients [9][13]. - The current clinical treatment options for rosacea are limited, with many recommended drugs not available in China, creating a pressing need for safe and effective innovative products [4][25]. - CKBA shows potential as a treatment for rosacea, with a clinical pipeline that is currently sparse, indicating a favorable competitive landscape for future development [9][19][23]. Summary by Sections Section 1: Demand for New Drugs - Rosacea is a chronic inflammatory disease affecting the central face, with a high psychological burden on patients, leading to a strong desire for treatment [13]. - A survey indicated that 95.3% of patients express a need for treatment, highlighting the urgency for new therapeutic options [13]. Section 2: CKBA Potential - CKBA has been shown to strongly inhibit the differentiation of Th17 cells, which are implicated in the pathogenesis of rosacea, suggesting its potential efficacy across various clinical manifestations of the disease [19][23]. - The global pipeline for rosacea treatments is limited, with only six active candidates since 2020, and domestic development is nearly non-existent [23]. Section 3: Investment Recommendations - Given the high demand and limited treatment options, the report recommends focusing on companies like 泰恩康 (Tainkang) for potential investment opportunities in the rosacea treatment space [4][25].